Advances in Engineered Nanoparticles for the Treatment of Ischemic Stroke by Enhancing Angiogenesis
DOI: https://doi.org/10.2147/ijn.s463333
IF: 7.033
2024-05-18
International Journal of Nanomedicine
Abstract:Guangtian Wang, 1, 2, &ast Zhihui Li, 3, &ast Gongchen Wang, 4, &ast Qixu Sun, 5 Peng Lin, 1 Qian Wang, 2 Huishu Zhang, 6 Yanyan Wang, 7 Tongshuai Zhang, 8 Feiyun Cui, 9 Zhaohua Zhong 1, 2 1 Teaching Center of Pathogenic Biology, School of Basic Medical Sciences, Harbin Medical University, Harbin, Heilongjiang, 150081, People's Republic of China; 2 Department of Microbiology, School of Basic Medical Sciences, Harbin Medical University, Harbin, Heilongjiang, 150081, People's Republic of China; 3 Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150086, People's Republic of China; 4 Department of Vascular Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150086, People's Republic of China; 5 Department of Gastroenterology, Penglai People's Hospital, Yantai, Shandong, 265600, People's Republic of China; 6 Teaching Center of Biotechnology, School of Basic Medical Sciences, Harbin Medical University, Harbin, Heilongjiang, 150081, People's Republic of China; 7 Teaching Center of Morphology, School of Basic Medical Sciences, Harbin Medical University, Harbin, Heilongjiang, 150081, People's Republic of China; 8 Department of Neurobiology, School of Basic Medical Sciences, Harbin Medical University, Harbin, Heilongjiang, 150081, People's Republic of China; 9 Department of Physiology, School of Basic Medical Sciences, Harbin Medical University, Harbin, Heilongjiang, 150081, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhaohua Zhong; Feiyun Cui, Email ; Angiogenesis, or the formation of new blood vessels, is a natural defensive mechanism that aids in the restoration of oxygen and nutrition delivery to injured brain tissue after an ischemic stroke. Angiogenesis, by increasing vessel development, may maintain brain perfusion, enabling neuronal survival, brain plasticity, and neurologic recovery. Induction of angiogenesis and the formation of new vessels aid in neurorepair processes such as neurogenesis and synaptogenesis. Advanced nano drug delivery systems hold promise for treatment stroke by facilitating efficient transportation across the the blood-brain barrier and maintaining optimal drug concentrations. Nanoparticle has recently been shown to greatly boost angiogenesis and decrease vascular permeability, as well as improve neuroplasticity and neurological recovery after ischemic stroke. We describe current breakthroughs in the development of nanoparticle-based treatments for better angiogenesis therapy for ischemic stroke employing polymeric nanoparticles, liposomes, inorganic nanoparticles, and biomimetic nanoparticles in this study. We outline new nanoparticles in detail, review the hurdles and strategies for conveying nanoparticle to lesions, and demonstrate the most recent advances in nanoparticle in angiogenesis for stroke treatment. Keywords: angiogenesis, ischemic stroke, nanoparticles, blood brain barrier, neurogenesis, neuroprotection therapy Graphical Ischemic stroke is a neurological condition caused by cerebrovascular stenosis or occlusion. It is the world's second-greatest cause of mortality and the major cause of long-term impairment in people. 1,2 Furthermore, as the world population ages, the prevalence of ischemic stroke rises. 3 Ischemia causes the irreversible creation of a damaged infarct core and the surrounding viable penumbra in the ischemic hemisphere. Early recanalization of occluded cerebral arteries by intravenous thrombolysis or mechanical thrombectomy to decrease infarcts while salvaging the penumbra is the gold standard of therapy. Unfortunately, the clinical treatment of ischemic stroke has several limitations and requires further development owing to the restricted temporal window of intravenous thrombolysis (within 3–4.5 h after start) and the absence of universal standardization of mechanical thrombectomy procedures. 4,5 Although thrombolytic therapy is strictly time-limited, timely thrombolysis can be effective in relieving neurological damage. 6 The recombinant fibrinogen activator tPA is the only effective thrombolytic agent approved by the US Food and Drug Administration (FDA) for clinical use in acute ischemic stroke. 7 With the development of new thrombolytic agents and advanced imaging techniques that enable longer thrombolysis times based on advanced imaging, the treatment time window has been extended to 6 h due to the short therapeutic window suitable for the majority of patient -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology